The biosimilar market will grow
An increase in the volume of the market of biological drugs is predicted
Pharmacy Online www.apteka.ua based on PharmExec materials: Global Biosimilars Market to Reach $2.4 Billion in 2013
According to the forecast of the British analytical company Visiongain (Biosimilars And Follow-On Biologics: World Market 2013-2023 – VM), the volume of the world market of biosimilars (bioengineers, biosimilars – VM) in 2013 will amount to 2.4 billion US dollars, annual growth will reach 20%, and it will account for 2% of the total market of biological drugs.
In the long term, a constant increase in the volume of the mentioned market is predicted for 10 years. The driver of this process will be the release of new biosimilars, which will be especially noted in the USA and EU countries. According to the Visiongain report, the highest growth rate will be characteristic of such groups of biosimilars as monoclonal antibodies and insulins, and in 2023 these drugs will account for more than 57% of the global pharmaceutical market of biosimilars in monetary terms.
In addition, the market volume of biosimilars of erythropoietin and filgrastim preparations, which are currently marketed in some developed countries, is expected to increase. Despite the fact that the revenues from the sales of these biosimilars are lower than from the sales of reference drugs, it is predicted that their release in the United States will help increase the volume of the pharmaceutical market of biosimilars starting in 2014.
Among the factors that contribute to the development of this positive dynamics, we can also name the introduction of such biosimilars to the market: filgrastim (pegfilgrastim) II generation and epoetin alpha (darbepoetin alpha).
James Evans, pharmaceutical market analyst, noted that new regulatory standards regarding the circulation of biosimilars have been approved in the EU countries. This contributed to a significant reduction of barriers to the introduction of drugs to the market. Thus, the attractiveness of the market has increased, which will positively affect its growth.
The leaders in terms of sales of biosimilars in 2012 were developing countries such as China and India. The USA, Japan and the EU countries accumulated 20% of the volume of this market in monetary terms. Over the next 10 years, according to the presented forecast, it is expected that higher growth rates of the biosimilar market will be observed in developed countries, the reason for which will be the expiration of patent protection of biological blockbuster drugs in 2013-2017.
Portal "Eternal youth" http://vechnayamolodost.ru28.05.2013